Abstract
The aim of the study was to evaluate whether adequate stem cells (CD34+) could be harvested at presentation in myeloma patients such that high dose melphalan (HDM) with autologous stem cell rescue can be offered as primary therapy. The regimes either involved no prior cytoreductive chemotherapy (steroids only, n = 31) or a single course of VAD (n = 22). The median number of CD34 cells collected with steroids was 1.3 x 10(6) (0.2-5.6) compared to 4.6 x 10(6) (0.3-19.2) cells/kg with VAD (P < 0.0001). We conclude that it is possible to collect stem cells from myeloma patients at presentation with minimal prior therapy. Using this strategy, of a single prior course of chemotherapy followed by immediate harvest, it is feasible to offer early high-dose therapy in clinical situations where this is important.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Blood Cell Count
-
Cyclophosphamide / pharmacology
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Administration Schedule
-
Feasibility Studies
-
Female
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / pharmacology
-
Hematopoietic Stem Cell Mobilization / methods*
-
Humans
-
Lenograstim
-
Leukapheresis
-
Male
-
Melphalan / therapeutic use
-
Methylprednisolone / pharmacology
-
Middle Aged
-
Multiple Myeloma / blood*
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / surgery
-
Peripheral Blood Stem Cell Transplantation*
-
Recombinant Proteins / pharmacology
-
Remission Induction
-
Time Factors
-
Vincristine / administration & dosage
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Vincristine
-
Lenograstim
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Filgrastim
-
Melphalan
-
Methylprednisolone